New drugs promise to change the therapeutic landscape of breast cancer. First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib. In a late-breaking presentation to the 2013 European Cancer Congress ...Saturday, 28 September 2013
Women With Advanced Breast Cancer may Benefit from Anti-Cancer Drug T-DM1
New drugs promise to change the therapeutic landscape of breast cancer. First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib. In a late-breaking presentation to the 2013 European Cancer Congress ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment